AGC Biologics vs SCTbio: CDMO Comparison
Side-by-side comparison of AGC Biologics and SCTbio on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- AGC Biologics has FDA inspections on record (1); SCTbio does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- AGC Biologics has materially broader EMA GMP coverage (23 active certificates vs 5) — stronger EU footprint.
On a 13-modality CDMO landscape, both AGC Biologics and SCTbio qualify as CAR-T manufacturers; SCTbio carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both AGC Biologics and SCTbio qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: AGC Biologics vs SCTbio
Which has the stronger FDA inspection record, AGC Biologics or SCTbio?
Both AGC Biologics and SCTbio maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. AGC Biologics has 1 FDA inspection on record; SCTbio has 0.
How do AGC Biologics and SCTbio compare on European GMP coverage?
AGC Biologics holds 23 active EMA GMP certificates and 0 MHRA / UK certificates. SCTbio holds 5 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — AGC Biologics or SCTbio?
AGC Biologics is matched to 2 ClinicalTrials.gov records as a manufacturing partner; SCTbio is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for CAR-T manufacturing — AGC Biologics or SCTbio?
Both AGC Biologics and SCTbio are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
AGC Biologics carries a Signal Score of 81/100 and SCTbio carries 82/100 — essentially tied for SCTbio. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →